Skip to main content
Premium Trial:

Request an Annual Quote

IP Update: Recent Patents Awarded to City of Hope, Alnylam, and More

Premium

Title: RNA Sequence-specific Mediators of RNA Interference

Patent Number: 8,790,922

Filed: Oct. 4, 2010

Lead Inventor: Thomas Tuschl, Max Planck Institute


Title: Double-stranded and Single-stranded RNA Molecules with 5' Triphosphates and Their Use for Inducing Interferon

Patent Number: 8,791,082

Filed: Sept. 21, 2007

Lead Inventor: John Rossi, City of Hope


Title: Nuclear Reprogramming Factor Comprising miRNA and a Protein Factor

Patent Number: 8,791,248

Filed: Dec. 7, 2011

Lead Inventor: Shinya Yamanaka, Kyoto University


Title: Compositions and Methods for Inhibiting Expression of the HAMP Gene

Patent Number: 8,791,250

Filed: May 23, 2013

Lead Inventor: Tomoko Nakayama, Alnylam Pharmaceuticals

The Scan

Steps for Quick Review

The US Food and Drug Administration is preparing for the quick review of drugs and vaccines for the Omicron variant, according to the Wall Street Journal.

Moving Away From Using Term 'Race'

A new analysis finds that geneticists are using the term "race" in their papers less than in years past, as Science reports.

Point of the Program

The Guardian writes that some scientists have called the design of a UK newborn sequencing program into question.

Science Papers Present Multi-Omic Analysis of Lung Cells, Regulation of Cardiomyocyte Proliferation

In Science this week: a multi-omic analysis of lung cells focuses on RIT1-regulated pathways, and more.